ROS1 rearrangements are potent oncogenic drivers in lung cancer. While identified in <2% of NSCLC, tumours positive for ROS1 rearrangements can be targeted by specific TKIs.
It has been determined that ROS1 rearrangements are not present alongside other oncogenic driver mutations, such as EGFR and ALK, therefore sequential testing is recommended.
Genetics - Cytogenetics
Lung cancer ROS1 status
· Only tissue preserved in neutral buffered formalin and paraffin embedded is suitable for use.
NB: Samples de-calcified in Formic acid are not suitable for FISH as this process affects the DNA integrity.
· Tissue specimens should be cut into sections of 2-4µm, ideally on poly-L-lysine slides.
· Ensure one H&E slide and 2-3 unprocessed slides are supplied.
· Slide must be clearly labelled with two patient identifiers, matching those on the request form.
The H&E slide must be assessed by a pathologist prior to receipt, and appropriate areas for analysis should be clearly marked.
Ambient (8 - 24 degrees Celsius)
Transport in slide-holders or boxes at room temperature.
ROS1 rearrangement is reported if more than 15% of cells examined show a signal pattern consistent with a clinically significant ROS1 rearrangement.
Rearrangements and copy number changes which have no proven clinical impact may also be detected using this probe. These will not be reported.
Fluorescence in situ hybridisation (FISH) on formalin fixed paraffin embedded (FFPE) tissue slides using a breakapart probe specific for the ROS1 rearrangement.
$518.68 (Exclusive of GST)